author-photo

Guido Giordano

Seconda Università degli Studi di Napoli

34

Papers

199

Citations

Citation Trend

Filter By

Papers (24) Sort By

Journal Conference Others

Nab paclitaxel (Nab-P) and gemcitabine (G) first line chemotherapy (CT) in metastatic pancreatic cancer (mPC) patients (pts) relapsed after adjuvant treatment (ADJ T): A “real life” study

2017 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

2017
Show All
- Source
- Cite
- Save
Citations (9)
Nab-paclitaxel in substitution of oxaliplatin and irinotecan in folfirinox schedule as first-line therapy in patients with metastatic pancreatic cancer: results of phase I dose finding of NabucCO study by GOIRC

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
F39Safety of Eribulin plus Trastuzumab in pre-treated HER2-positive advanced breast cancer (ABC) patients: results from an Italian observational study

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer

2015 Journal of Experimental & Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (39)
Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
The pretreatment neutrophil-lymphocyte ratio (NLR) as a predictor of outcome in a cohort of metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
2334 Nab Paclitaxel (Nab-P) and Gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): An Italian “real life” study

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)